Literature DB >> 18394306

Clostridium difficile surveillance trends, Saxony, Germany.

Florian Burckhardt, Anett Friedrich, Dietmar Beier, Tim Eckmanns.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18394306      PMCID: PMC2570926          DOI: 10.3201/eid1404.071023

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Vonberg et al. () recently commented on the increase of Clostridium difficile seen in US hospitals by using discharge diagnoses and confirmed the observation from the United States () with hospital discharge data from Germany during 2000 through 2004. C. difficile ribotype 027 has recently been isolated in Germany (). We further contribute to the assessment of C. difficile as an emerging threat by looking at population surveillance data. C. difficile is not a federal notifiable disease in Germany, which limits our ability to analyze national surveillance trends. However, in 2002 the state of Saxony implemented additional mandatory surveillance of community- and hospital-acquired infectious enteritis caused by laboratory-confirmed C. difficile. To check for an increase in notifications due to reporting bias of gastroenteric diseases, we compared the quarterly incidence data from 2002 through 2006 with data on Salmonella spp. infections (usually reported by local general practitioners) and rotavirus and norovirus infections (both usually reported by clinics). The potential problem of reporting bias for gastroenteric diseases has been addressed recently (). Information about age and sex of C. difficile patients was available for 2006 only. Quarterly incidences for C. difficile in Saxony were from 1.7–3.8 per 100,000 population in 2002 and 2003 and continued to increase to 14.8 cases per 100,000 population in 2006 (Figure). This constitutes a 6-fold increase of the yearly average of C. difficile incidence rates between 2002 and 2006. The third quarter of 2005 experienced a sharp drop that could not be explained retrospectively and might have resulted from transition to new procedures for data collection and management.
Figure

Quarterly incidence per 100,000 population of Clostridium difficile infections compared with gastroenteric infections caused by Salmonella spp., rotaviruses, and noroviruses in Saxony, Germany, 2002–2006. Note the log scale on the y axis.

Quarterly incidence per 100,000 population of Clostridium difficile infections compared with gastroenteric infections caused by Salmonella spp., rotaviruses, and noroviruses in Saxony, Germany, 2002–2006. Note the log scale on the y axis. Gastroenteric infections showed clear seasonality with a slightly decreasing yearly trend for Salmonella spp. and seasonal values from 13.8 cases per 100,000 in winter to summer peaks of 56.8. Rotavirus infections displayed an even stronger seasonality, with values from 7.0 cases per 100,000 in summer to winter peaks of 140.3. Norovirus infections peaked again during winter, at 137.2 cases per 100,000 but had as few as 11.0 cases per 100,000 during summer. Notification does not suggest reporting bias of gastroenteric infections. Elderly persons, i.e., those >65 years of age, were affected most by C. difficile infections; this age group accounted for 1,506 (65%) of all cases (n = 2,306) in 2006. The 45- to 64-year age group had the next highest number of cases, 451 (20%). Men and women were affected equally in the different age groups; slightly more women (n = 805) than men (n = 701) with C. difficile infection were >65 years of age. According to state and local health departments, there were no major health campaigns since 2004 that might have selectively increased awareness for C. difficile notification. Our results show a continuous increase of cases that even reaches seasonal notification levels of Salmonella spp. and Rotavirus infections, but the increase is difficult to explain entirely by changes in reporting behavior. We emphasize the role of individual German states in setting additional surveillance targets for public health. Given the epidemic potential and the severity of the disease, especially among the elderly, surveillance of C. difficile should be introduced throughout Germany along with enhanced prevention and treatment strategies ().
  5 in total

1.  Viral gastroenteritis increases the reports of Clostridium difficile infection.

Authors:  M Wilcox; W Fawley
Journal:  J Hosp Infect       Date:  2007-07-27       Impact factor: 3.926

2.  Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany.

Authors:  N Kleinkauf; B Weiss; A Jansen; T Eckmanns; B Bornhofen; E Küehnen; H-P Weil; H Michels
Journal:  Euro Surveill       Date:  2007-11-15

3.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

4.  Clostridium difficile in discharged inpatients, Germany.

Authors:  Ralf-Peter Vonberg; Frank Schwab; Petra Gastmeier
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

5.  Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.

Authors:  L Clifford McDonald; Maria Owings; Daniel B Jernigan
Journal:  Emerg Infect Dis       Date:  2006-03       Impact factor: 6.883

  5 in total
  32 in total

1.  High Mortality Risk in Chronic Kidney Disease and End Stage Kidney Disease Patients with Clostridium Difficile Infection: A Systematic Review and Meta-analysis.

Authors:  Charat Thongprayoon; Wisit Cheungpasitporn; Parkpoom Phatharacharukul; Pailin Mahaparn; Jackrapong Bruminhent
Journal:  J Nat Sci       Date:  2015-04

2.  Age and gender differences in Clostridium difficile-related hospitalization trends in Madrid (Spain) over a 12-year period.

Authors:  M D Esteban-Vasallo; S Naval Pellicer; M F Domínguez-Berjón; M Cantero Caballero; Á Asensio; G Saravia; J Astray-Mochales
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-04-07       Impact factor: 3.267

Review 3.  Clostridium difficile infection: guideline-based diagnosis and treatment.

Authors:  Christoph Lübbert; Endres John; Lutz von Müller
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

Review 4.  Chronic kidney disease and end-stage renal disease are risk factors for poor outcomes of Clostridium difficile infection: a systematic review and meta-analysis.

Authors:  C Thongprayoon; W Cheungpasitporn; P Phatharacharukul; P J Edmonds; Q Kaewpoowat; P Mahaparn; J Bruminhent; S B Erickson
Journal:  Int J Clin Pract       Date:  2015-07-05       Impact factor: 2.503

5.  Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.

Authors:  Diane M Citron; Kerin L Tyrrell; Suzanne E Dale; Laurent Chesnel; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

Review 6.  Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.

Authors:  Patrizia Spigaglia
Journal:  Ther Adv Infect Dis       Date:  2016-02

Review 7.  [Clostridium difficile infections in geriatric patients].

Authors:  R Simmerlein; A Basta; M Gosch
Journal:  Z Gerontol Geriatr       Date:  2016-10-26       Impact factor: 1.281

8.  Fecal transplant in refractory Clostridium difficile colitis.

Authors:  Alexander Kleger; Jacqueline Schnell; Andreas Essig; Martin Wagner; Martin Bommer; Thomas Seufferlein; Georg Härter
Journal:  Dtsch Arztebl Int       Date:  2013-02-15       Impact factor: 5.594

Review 9.  Acid suppression and the risk of Clostridium difficile infection.

Authors:  Ethan A Mezoff; Mitchell B Cohen
Journal:  J Pediatr       Date:  2013-06-05       Impact factor: 4.406

10.  Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults.

Authors:  Krishna Rao; Dejan Micic; Elizabeth Chenoweth; Lili Deng; Andrzej T Galecki; Cathrin Ring; Vincent B Young; David M Aronoff; Preeti N Malani
Journal:  J Am Geriatr Soc       Date:  2013-09-19       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.